In a significant advancement for cardiovascular medicine, Medtronic has announced that its innovative Sphere-9 catheter, integrated with the Affera mapping and ablation system, has received the CE mark in Europe for the treatment of ventricular arrhythmias. This regulatory milestone marks a major evolution in how clinicians manage heart rhythm disorders, positioning the dual-energy system as a frontrunner in the treatment of complex, often life-threatening, heart conditions.
By securing this expanded indication, Medtronic has cemented the Sphere-9 as the first all-in-one mapping and ablation, dual-energy catheter to be CE marked for ventricular ablation. This development not only broadens the therapeutic scope of the Affera platform but also signals a strategic push by the medical technology giant to capture a larger share of the fast-growing electrophysiology market.
The Evolution of the Affera Platform: A Chronology of Innovation
The journey of the Sphere-9 and Affera system to its current state of regulatory maturity has been marked by a series of high-impact milestones, reflecting Medtronic’s commitment to iterating on its cardiac ablation portfolio.
Initial Launch and Early Adoption
The Affera system first made waves in the medical community when it secured its initial CE mark in March 2023. At that time, the system was indicated for the treatment of common atrial arrhythmias, specifically atrial fibrillation and cavotricuspid isthmus (CTI)-dependent atrial flutter. This initial success demonstrated the efficacy of the catheter’s design, which integrates mapping and ablation into a single, cohesive workflow.
US Market Entry
Following its European success, the system crossed the Atlantic to secure approval from the US Food and Drug Administration (FDA) in October 2024. The FDA clearance validated the system’s utility for treating the same atrial conditions, setting the stage for its widespread integration into US clinical practice.
The Pivot to Ventricular Arrhythmias
The transition from treating atrial conditions to the more complex ventricular space was a calculated strategic shift. In April 2026, the potential of the system was further underscored when Medtronic received Breakthrough Device Designation from the FDA for the treatment of ventricular arrhythmias. This designation fast-tracked the regulatory process and highlighted the clinical urgency of addressing ventricular tachycardia (VT), a condition where the lower chambers of the heart beat at dangerously high speeds, often following a myocardial infarction (heart attack) or as a secondary complication of advanced heart disease.
The Technical Edge: What Sets Sphere-9 Apart
The Sphere-9 catheter distinguishes itself through its unique dual-energy capabilities. Unlike conventional systems that rely on a single energy source, or even Medtronic’s own PulseSelect—which utilizes a fixed 9-electrode single-shot catheter—the Sphere-9 is an all-in-one, versatile tool.
Dual-Energy Versatility
The system combines pulsed field ablation (PFA) and radiofrequency (RF) ablation. This dual-energy approach allows physicians to customize their treatment strategy based on the specific anatomical needs of the patient and the characteristics of the arrhythmia. PFA has emerged as a revolutionary, non-thermal energy source that minimizes damage to surrounding healthy tissue, while RF remains a gold standard for precise lesion creation. By housing both within a single catheter, Medtronic enables surgeons to map and ablate with unprecedented efficiency.
Competitive Positioning
In the highly competitive landscape of cardiac ablation, the Sphere-9 faces stiff competition, most notably from Boston Scientific’s Farapulse system. While Farapulse has garnered significant market attention for its performance in atrial fibrillation, it currently lacks the expanded indications for ventricular arrhythmia that Medtronic has now secured in Europe. This provides Medtronic with a distinct "first-mover" advantage in the ventricular space, potentially shifting the referral patterns of electrophysiologists toward the Affera platform.
Clinical Evidence and Supporting Data
The regulatory success of the Sphere-9 is underpinned by rigorous clinical investigation. At the Heart Rhythm Society (HRS) Annual Meeting in April 2026, Medtronic presented compelling data from an early feasibility study evaluating the Sphere-9 in the treatment of recurrent sustained monomorphic VT in post-myocardial infarction patients.
Key Study Findings
The data revealed that 65.5% of patients treated at various centers across the United States remained free from VT recurrence six months post-ablation. This statistic is highly encouraging for the clinical community, as ventricular tachycardia is notoriously difficult to manage and often carries a poor prognosis if not treated effectively.
The Sphere VT Trial
Building on this success, Medtronic is currently conducting the "Sphere VT" trial (NCT07585968). This investigational device exemption (IDE) trial is specifically designed to generate the robust safety and efficacy data required for a formal FDA submission for ventricular arrhythmia clearance in the United States. The trial is expected to be a cornerstone of Medtronic’s future regulatory filings, serving as the final piece of evidence needed to replicate their European success in the American market.
Official Perspectives: Leadership and Vision
The executive leadership at Medtronic views this expansion as a critical pillar of their long-term growth strategy within the electrophysiology business.
"This milestone is a major step forward as we continue to expand the footprint of the Affera technology to more physicians and patients," stated Rebecca Seidel, president of Medtronic’s electrophysiology therapies business. Seidel emphasized that the expansion into ventricular arrhythmias represents a "fast-growing market opportunity," fueled by the inherent versatility and safety profile of the Sphere-9 catheter.
Dr. Khaldoun Tarakji, vice president and Chief Medical Officer of Medtronic’s cardiac ablation solutions business, echoed this sentiment, highlighting the human impact of the technology. "Physicians have long needed better tools for ventricular arrhythmias," Tarakji noted. "We’re proud to deliver a technology that addresses this unmet need and moves the needle on patient care." By moving into the ventricular space, Medtronic is addressing a clinical population that has historically been underserved by the limitations of older ablation technologies.
Implications for the Future of Cardiac Care
The CE mark expansion for the Sphere-9 system carries several profound implications for the medical device industry and the patients it serves.
Improving Patient Outcomes
Ventricular arrhythmias represent a significant burden on the healthcare system and the quality of life of patients. By providing a safer, more efficient tool for ablation, Medtronic is effectively reducing the risk of recurrence and minimizing the long-term dependency on anti-arrhythmic medications or internal cardiac defibrillators (ICDs).
Redefining the Standard of Care
The transition toward all-in-one, dual-energy catheters signifies a shift away from the "one-size-fits-all" approach to electrophysiology. As more centers adopt the Affera platform, the standard of care for complex arrhythmias is expected to become more standardized, leading to shorter procedure times and improved procedural success rates.
The Path Toward Global Adoption
While the European market now has access to this technology, the focus for Medtronic now shifts to completing the Sphere VT trial and finalizing the FDA approval process. Should the FDA follow the precedent set by European regulators, it would solidify the Sphere-9 as a global standard for ventricular ablation.
As Medtronic continues to build on its momentum, the medical community will be watching the Sphere VT trial results closely. With its unique combination of mapping and dual-energy ablation, the Sphere-9 is not just an incremental improvement—it is a transformative tool that promises to change the trajectory of life-saving heart rhythm treatment for years to come.
About the Author
